New cancer drug combo enters human testing
NCT ID NCT05007782
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors. It is a first-in-human study, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Denikitug (GS-1811) and zimberelimab
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
- What could go wrong
- This is an early phase 1 trial focused on safety and dosing, not yet on effectiveness. Many experimental cancer drugs fail in early testing, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital
RECRUITINGTaoyuan City, 33308, Taiwan
-
Changhua Christian Hospital
RECRUITINGChanghua, 500, Taiwan
-
Chi Mei Hospital, Liouying
RECRUITINGTainan, 73657, Taiwan
-
Chris O'Brien Lifehouse
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
Clinica Universidad de Navarra
RECRUITINGPamplona, 31008, Spain
-
Hospital Universitari Vall d´Hebrón
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Quironsalud Madrid
RECRUITINGMadrid, 28223, Spain
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
MD Anderson Cancer Center
RECRUITINGMadrid, 28033, Spain
-
Monash Medical Centre
RECRUITINGClayton, Victoria, 3168, Australia
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
National Taiwan University Cancer Center (NTUCC)
RECRUITINGTaipei, 100229, Taiwan
-
National Taiwan University Hospital
RECRUITINGTaipei, 100, Taiwan
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Sarah Cannon Research Institute at Mary Crowley
RECRUITINGDallas, Texas, 75230, United States
-
Smilow Cancer Center
COMPLETEDNew Haven, Connecticut, 06510, United States
-
Stanford Cancer Center
RECRUITINGPalo Alto, California, 94305, United States
-
Taipei Tzu Chi General Hospital
WITHDRAWNTaipei, 110, Taiwan
-
Taipei Veterans General Hospital
RECRUITINGTaipei, 11217, Taiwan
-
Tennessee Oncology, PLLC
RECRUITINGNashville, Tennessee, 37203, United States
-
University Health Network, Princess Margaret Cancer Centre
RECRUITINGToronto, M5G 2M9, Canada
-
University of California San Diego
RECRUITINGLa Jolla, California, 92093, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 39090, United States
-
University of Wisconsin Clinical Sciences Center
RECRUITINGMadison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?